{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 22 of 60', 'Randomization will occur before the first dose of study drug during the Treatment Period and', 'may occur on either Day - -1 or Day 1. Randomization and stratification details are provided in', 'Section 9.2.', 'To enter the Treatment Period, subjects must have stable CF disease (as judged by the', 'investigator) and have remained on a stable CF treatment regimen during the TEZ/IVA Run-in', 'Period. If these conditions are not met (for example, if the subject has an acute upper or lower', 'respiratory infection, PEx, or changes in therapy [including antibiotics] for sinopulmonary', 'disease within 28 days before the Day 1 Visit [first dose of study drug in the Treatment Period]),', 'subjects may be rescreened once (Section 9.1.1.2) and re-enter the TEZ/IVA Run-in Period on', 'Day -28.', 'Subjects who prematurely discontinue study drug treatment during the Treatment Period will', 'remain in the study from the time of discontinuation of study drug treatment through the last', 'scheduled study visit and complete the assessments for all study visits, as described in', 'Section 9.1.5.2.', '9.1.4', 'Follow-up', 'The Safety Follow-up Visit will occur approximately 28 ( 7) days after the last dose of study', 'drug for subjects who complete study drug dosing and for subjects who prematurely discontinue', 'study drug dosing, as described in Section 9.1.5.', 'An open-label roll-over study will be available for subjects who complete the Week 24 Visit and', 'are eligible. The Safety Follow-up Visit is not required for subjects who complete the Week 24', 'Visit and enroll in an open-label roll-over study within 28 days after the last dose of study drug.', '9.1.5', 'Early Termination of Treatment', 'If a subject prematurely discontinues study drug treatment, an Early Termination of Treatment', '(ETT) Visit should be scheduled as soon as possible after the decision to discontinue treatment.', 'Subjects who prematurely discontinue treatment will also be required to complete the Safety', 'Follow-up Visit, approximately 28 days after their last dose of study drug. The assessments', 'performed at the Safety Follow-up Visit are listed in Table 3-2.', 'If the ETT Visit occurs 3 weeks or later following the last dose of study drug, then the ETT Visit', 'will replace the Safety Follow-up Visit, and a separate Safety Follow-up Visit will not be', 'required.', 'If a subject withdraws from the study and also withdraws consent or assent, no further', 'assessments will be performed. Vertex may retain and continue to use any data and samples', 'collected before such withdrawal of consent or assent.', '9.1.5.1', 'Discontinuation During the Run-in Period', 'Subjects who prematurely discontinue study drug treatment during the TEZ/IVA Run-in Period', 'will not be randomized or participate in the Treatment Period. These subjects will complete an', 'ETT Visit and Safety Follow-up Visit (as applicable; see Section 9.1.5). The Safety Follow-up', 'Visit will be their last visit in the study.', '9.1.5.2', 'Discontinuation During the Treatment Period', 'Subjects who prematurely discontinue study drug treatment during the Treatment Period will', 'continue to complete all scheduled study visits following completion of the ETT Visit, as', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 23 of 60', 'detailed in Table 3-2. These subjects will complete an ETT Visit and Safety Follow-up Visit (as', 'applicable; see Section 9.1.5).', '9.1.6', 'Lost to Follow-up', 'A subject will be considered lost to follow-up if both of the following occur:', 'The subject misses 2 consecutive study visits (telephone contact and/or clinic visit) and is', 'subsequently unable to be contacted by telephone (3 documented attempts by telephone', 'within 2 weeks following the second missed visit).', 'The subject does not respond within 2 weeks to a registered letter sent after the 3 attempted', 'telephone contacts.', '9.1.7', 'Completion of Study Participation', 'Completion of study participation for each individual subject is defined as one of the following:', 'For subjects who complete the Treatment Period and enter an open-label study within', '28 days of the Week 24 Visit: the Week 24 Visit', 'For subjects who complete the Treatment Period and do not enter an open-label study within', '28 days of the Week 24 Visit: the Safety Follow-up Visit', 'For subjects who prematurely discontinue study drug treatment during the Treatment Period', 'but do not withdraw consent (and assent, as applicable): The latest of the Week 24 Visit, ETT', 'Visit, or Safety Follow-up Visit (if required)', 'For subjects who prematurely discontinue study drug treatment during the TEZ/IVA Run-in', 'Period but do not withdraw consent (and assent, as applicable): the ETT or Safety Follow-up', 'Visit (if required)', 'For subjects who withdraw consent or assent: date of withdrawal of consent or assent,', 'whichever is earlier (Section 9.9)', 'If subjects are lost to follow-up (Section 9.1.6), the date of completion of study participation will', 'be defined as the date of the last contact.', 'The end of study is defined in Section 13.2.8.', '9.2', 'Method of Assigning Subjects to Treatment Groups', 'Subjects will be randomized (1:1) to the VX-445/TEZ/IVA or TEZ/IVA group. Randomization', 'will be stratified by ppFEV1 determined during the TEZ/IVA Run-in Period (Day - -14', 'assessment; <70 versus 70), age at the Screening Visit (<18 versus >18 years of age), and', 'whether the subject is receiving CFTR modulator treatment at the Screening Visit (yes versus', 'no). If the Day - -14 ppFEV1 value is not valid or not available, the most recent available ppFEV1', 'value will be used for stratification.', 'An interactive web response system (IWRS) will be used to assign subjects to treatment. The', 'randomization code list will be produced by Vertex Biometrics or a qualified randomization', 'vendor.', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}